ArticleFrontiers in bioengineering and biotechnology2026
Region-dependent expression and function of integrin α5β1 in protecting against disc degeneration
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanotransduction in intervertebral disc degeneration: from compartment-specific sensors to translational frontiers.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Abnormal mechanical loading is a significant pathogenic factor in intervertebral disc degeneration (IVDD), yet the underlying mechanotransduction mechanisms remain incompletely elucidated. This study aimed to investigate the role of integrin α5β1 as a key mechanosensor in regulating the autophagy-apoptosis balance under mechanically induced IVDD. Methods: Bovine intervertebral discs (IVDs) with intact endplates were cultured in a bioreactor and subjected to dynamic mechanical loading, including physiological loading (PL: 0.02-0.2 MPa, 0.2 Hz) and degenerative loading (DL: 0.32-0.5 MPa, 5 Hz) for 3 and 7 days. Interventions involved the autophagy inhibitor 3-Methyladenine (3-MA), integrin α5β1-specific inhibitory peptide RGD (Arg-Gly-Asp), and the autophagy activator rapamycin. A systematic evaluation was performed, assessing disc height, histomorphology, cell viability, gene/protein expression, autophagy levels, and apoptosis. Results: Degenerative loading induced progressive IVD degeneration, characterized by irreversible disc height loss, structural disruption, decreased cell viability, and extracellular matrix (ECM) metabolic imbalance. Treatment with 3-MA exacerbated these degenerative changes, confirming the protective role of autophagy. Integrin α5β1 exhibited distinct spatial distribution patterns: its expression was significantly upregulated in the nucleus pulposus (NP) and inner annulus fibrosus (IAF) under degenerative loading, whereas only the β1 subunit was increased in the outer annulus fibrosus (OAF). Functional experiments demonstrated that competitive inhibition of integrin α5β1 by RGD peptide significantly suppressed autophagy activity, exacerbated apoptosis, and promoted ECM degradation. Conversely, rapamycin alleviated degeneration by restoring autophagic flux. Mechanistically, degenerative loading suppressed the FAK/PI3K/AKT/mTOR pathway while upregulating ULK1, and these effects were partially reversed by RGD inhibition. Discussion: The autophagy-apoptosis balance plays a critical regulatory role in IVDD progression, with integrin α5β1 serving as a crucial upstream mechanosensor that may exert its protective function through modulating the FAK/PI3K/AKT/mTOR pathway. The region-specific distribution of integrin subtypes determines the specificity of mechanotransduction across different disc areas. Targeting the integrin-autophagy axis and its associated signaling pathways may represent a potential therapeutic strategy for mitigating mechanically induced IVDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.